Development of a Fluorescent Multiplex Assay for Detection of MSI‐High Tumors
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Determining whether a tumor exhibits microsatellite instability (MSI) is useful in identifying patients with hereditary non‐polyposis colorectal cancer and sporadic gastrointestinal cancers with defective DNA mismatch repair (MMR). The assessment of MSI status aids in establishing a clinical prognosis and may be predictive of tumor response to chemotherapy. A reference panel of five markers was suggested for MSI analysis by a National Cancer Institute (NCI) workshop in 1997 that has helped to standardize testing. But this panel of markers has limitations resulting from the inclusion of dinucleotide markers, which are less sensitive and specific for detection of tumors with MMR deficiencies compared to other types of markers that are currently available. This study demonstrates that mononucleotides are the most sensitive and specific markers for detection of tumors with defects in MMR and identifies an optimal panel of markers for detection of MSI‐H tumors. A set of 266 mono‐, di‐, tetra‐ and penta‐nucleotide repeat microsatellite markers were used to screen for MSI in colorectal tumors. The best markers for detection of MSI‐H tumors were selected for a MSI Multiplex System, which included five mononucleotide markers: BAT-25, BAT-26, NR-21, NR-24 and MONO-27. In addition, two pentanucleotide markers were added to identify sample mix‐ups and/or contamination. We classified 153 colorectal tumors using the new MSI Multiplex System and compared the results to those obtained with a panel of 10 microsatellite markers combined with immunohistochemical (IHC) analysis. We observed 99% concordance between the two methods with nearly 100% accuracy in detection of MSI‐H tumors. Approximately 5% of the MSI‐H tumors had normal levels of four MMR proteins and as a result would have been misclassified based solely on IHC analysis, emphasizing the importance of performing MSI testing. The new MSI Multiplex System offers several distinct advantages over other methods of MSI testing in that it is both extremely sensitive and specific and amenable to high‐throughput analysis. The MSI Multiplex System meets the new recommendations proposed at the recent 2002 NCI workshop on HNPCC and MSI testing and overcomes problems inherent to the original five‐marker panel. The use of a single multiplex fluorescent MSI assay reduces the time and costs involved in MSI testing with increased reliability and accuracy and thus should facilitate widespread screening for microsatellite instability in tumors of patients with gastrointestinal cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“STR loci are known to vary in the presence of microsatellite instability, with the degree of variability depending on the locus being assessed.16,28,43”
From Match criteria for human cell line authentication: Where do we draw the line? (2013) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Self-citationUmar, A., Boland, C. R., Terdiman, J. P., Syngal, S., Chapelle, A. D. L., Ruschoff, J., Fishel, R., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,183
Self-citationMicrosatellite Instability in Cancer of the Proximal Colon
Thibodeau, S. N., Bren, G., & Schaid, D. (1993) · Science · doi:10.1126/science.8484122 · Cited by 3,130 · cited 2×
“ity (MSI), which is characterized by alterations in the length of short tandem repeats in tumor DNA [1,16,44].”
BackgroundResultSelf-citationThe human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
Fishel, R., Lescoe, M. K., Rao, M. R. S., Copeland, N. G., Jenkins, N. A., Garber, J., Kane, M., & Kolodner, R. (1993) · Cell · doi:10.1016/0092-8674(93)90546-3 · Cited by 2,873 · cited 1×
“Microsatellite instability is caused by DNA mismatch repair (MMR) deficiency and subsequent failure to repair errors introduced during replication of DNA [6,11, 22].”
BackgroundClues to the Pathogenesis of Familial Colorectal Cancer
Aaltonen, L. A., Peltomäki, P., Leach, F. S., Sistonen, P., Pylkkänen, L., Mecklin, J.-P., Järvinen, H., Powell, S. M., Jen, J., Hamilton, S. R., et al. (1993) · Science · doi:10.1126/science.8484121 · Cited by 2,710 · cited 2×
“MSI-H tumors are more likely to have mutations in genes with short repetitive tracts includingTGF-βRII, BAX, IGF2R genes [27,30, 32,34,42,50] and less likely to have loss of APC [1,15, 31,38] or have mutations in p53 [1,7,24,31,38,41] and K-ras genes [1,24,31,38].”
BackgroundIonov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D., & Perucho, M. (1993) · Nature · doi:10.1038/363558a0 · Cited by 2,708 · cited 1×
“ity (MSI), which is characterized by alterations in the length of short tandem repeats in tumor DNA [1,16,44].”
BackgroundMutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
Leach, F. S., Nicolaides, N. C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Peltomäki, P., Sistonen, P., Aaltonen, L. A., Nyström-Lahti, M., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90330-s · Cited by 2,276 · cited 1×
“Microsatellite instability is caused by DNA mismatch repair (MMR) deficiency and subsequent failure to repair errors introduced during replication of DNA [6,11, 22].”
BackgroundInactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270 · cited 1×
“MSI-H tumors are more likely to have mutations in genes with short repetitive tracts includingTGF-βRII, BAX, IGF2R genes [27,30, 32,34,42,50] and less likely to have loss of APC [1,15, 31,38] or have mutations in p53 [1,7,24,31,38,41] and K-ras genes [1,24,31,38].”
BackgroundRibic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Self-citationBronner, C. E., Baker, S. M., Morrison, P. T., Warren, G., Smith, L. G., Lescoe, M. K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., et al. (1994) · Nature · doi:10.1038/368258a0 · Cited by 2,052 · cited 1×
“Microsatellite instability is caused by DNA mismatch repair (MMR) deficiency and subsequent failure to repair errors introduced during replication of DNA [6,11, 22].”
Background
Cited by
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Landscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H.-Z., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,476
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034
Classification and characterization of microsatellite instability across 18 cancer types
Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 991
Microsatellite Instability as a Biomarker for PD-1 Blockade
Dudley, J. C., Lin, M.-T., Le, D. T., & Eshleman, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1678 · Cited by 931
Enhanced prime editing systems by manipulating cellular determinants of editing outcomes
Chen, P. J., Hussmann, J. A., Yan, J., Knipping, F., Ravisankar, P., Chen, P.-F., Chen, C., Nelson, J. W., Newby, G. A., Sahin, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.018 · Cited by 809
“, 1997), microsatellite instability is used clinically as a measure of MMR activity in colorectal cancers (Bacher et al., 2004; Umar et al., 2004).”
BackgroundA molecular portrait of microsatellite instability across multiple cancers
Cortes-Ciriano, I., Lee, S., Park, W.-Y., Kim, T.-M., & Park, P. J. (2017) · Nature Communications · doi:10.1038/ncomms15180 · Cited by 658
Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 556
Microsatellite instability: a review of what the oncologist should know
Li, K., Luo, H., Huang, L., Luo, H., & Zhu, X. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1091-8 · Cited by 509
Palomaki, G. E., McClain, M. R., Melillo, S., Hampel, H. L., & Thibodeau, S. N. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e31818fa2db · Cited by 467
Self-citationMolecular Classification and Correlates in Colorectal Cancer
Ogino, S., & Goel, A. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070082 · Cited by 460
Vanderwalde, A., Spetzler, D., Xiao, N., Gatalica, Z., & Marshall, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1372 · Cited by 458
“High TMB and MSI- H had 95% overlap for CRC, which was expected, as the TMB cutoff was based on CRC MSI- FA results.”
MethodInfluentialMicrosatellite Instability Detection by Next Generation Sequencing
Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H., & Pritchard, C. C. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.223677 · Cited by 399
Colorectal cancer molecular biology moves into clinical practice
Pritchard, C. C., & Grady, W. M. (2011) · Gut · doi:10.1136/gut.2009.206250 · Cited by 344
Microsatellite instability in colorectal cancer
Söreide, K., Janssen, E. A. M., Söiland, H., Körner, H., & Baak, J. P. A. (2006) · British Journal of Surgery · doi:10.1002/bjs.5328 · Cited by 302
Immunotherapy, Inflammation and Colorectal Cancer
Lichtenstern, C. R., Ngu, R. K., Shalapour, S., & Karin, M. (2020) · Cells · doi:10.3390/cells9030618 · Cited by 294
“Current methods include the amplification and examination of polymerase chain reaction (PCR) products from commonly affected microsatellite markers in tumors [34,37,38].”
MethodMicrosatellite instability in colorectal cancer
IACOPETTA, B., GRIEU, F., & AMANUEL, B. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01335.x · Cited by 289
Murphy, K. M., Zhang, S., Geiger, T., Hafez, M. J., Bacher, J., Berg, K. D., & Eshleman, J. R. (2006) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050092 · Cited by 281
Self-citationChoi, Y. Y., Kim, H., Shin, S.-J., Kim, H. Y., Lee, J., Yang, H.-K., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y. K., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002803 · Cited by 239
Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer
Steinert, G., Schölch, S., Niemietz, T., Iwata, N., García, S. A., Behrens, B., Voigt, A., Kloor, M., Benner, A., Bork, U., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1885 · Cited by 233
Zhang, L. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080062 · Cited by 213
Adrenocortical carcinoma is a Lynch syndrome-associated cancer
Raymond, V. M., Everett, J. N., Furtado, L. V., Gustafson, S. L., Jungbluth, C. R., Gruber, S. B., Hammer, G. D., Stoffel, E. M., Greenson, J. K., Giordano, T. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.0988 · Cited by 208
“In short, five mononucleotide repeat markers are used for MSI determination (BAT-26, NR-21, BAT-25, MONO-27, and NR-24) and two pentanucleotide markers for establishing sample identity (Penta C and Penta D).(18) Amplicons were separated by capillary electrophoresis using an automated ABI Prism 3130XL Genetic Analyzer…”
MethodGrady, W. M., & Markowitz, S. D. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3444-4 · Cited by 195
“MSI CRC has been defined by the presence of at least 30 % unstable microsatellite loci in a panel of 5–10 loci consisting of mono- and dinucleotide tracts selected at a National Cancer Institute consensus conference [24], although currently, many clinical laboratories assess MSI using a panel of 5 mononucleotide marke…”
Match criteria for human cell line authentication: Where do we draw the line?
Capes‐Davis, A., Reid, Y. A., Kline, M. C., Storts, D. R., Strauss, E., Dirks, W. G., Drexler, H. G., MacLeod, R. A. F., Sykes, G., Kohara, A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27931 · Cited by 180
“16,28,43 A greater number of loci may give sufficient data for discrimination, but for cell lines with microsatellite instability, an alternate method such as single nucleotide polymorphism (SNP) analysis should also be considered.”
MethodMSH2 Loss in Primary Prostate Cancer
Guedes, L. B., Antonarakis, E. S., Schweizer, M. T., Mirkheshti, N., Almutairi, F., Park, J. C., Glavaris, S., Hicks, J., Eisenberger, M. A., De Marzo, A. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0955 · Cited by 156
“Overall, only 61% (8/13) of these had evidence of MSI by PCR, although analysis was frequently limited by low overall DNA amplification level (48, 49).”
BackgroundMooi, J. K., Wirapati, P., Asher, R., Lee, C. K., Savas, P., Price, T. J., Townsend, A., Hardingham, J., Buchanan, D., Williams, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy410 · Cited by 145
“MSI was determined by analysis of genomic DNA purified from FFPE tumour sections, using the MSI Analysis System (Promega) [6].”
MethodFindeisen, P., Kloor, M., Merx, S., Sutter, C., Woerner, S. M., Dostmann, N., Benner, A., Dondog, B., Pawlita, M., Dippold, W., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4146 · Cited by 134
Ogino, S., Meyerhardt, J. A., Kawasaki, T., Clark, J. W., Ryan, D. P., Kulke, M. H., Enzinger, P. C., Wolpin, B. M., Loda, M. F., & Fuchs, C. S. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0398-3 · Cited by 130
“BAT25 and BAT26 were the most predictive markers among the five markers in the US National Cancer Institute (NCI) consensus panel [3].”
BackgroundBaudhuin, L. M., Burgart, L. J., Leontovich, O. N., & Thibodeau, S. N. (2005) · Familial Cancer · doi:10.1007/s10689-004-1447-6 · Cited by 129
“However, because of this relative stability, they also serve as excellent markers for quality control purposes [56].”
BackgroundSelf-citationMolecular Alterations and Biomarkers in Colorectal Cancer
Grady, W. M., & Pritchard, C. C. (2014) · Toxicologic Pathology · doi:10.1177/0192623313505155 · Cited by 104
“Currently, many clinical laboratories assess MSI using a panel of 5 mononucleotide markers (BAT-25, BAT-26, NR-21, NR-24, and MONO-27) that were selected for high sensitivity and specificity (Bacher et al. 2004).”
BackgroundMicrosatellite instability in prostate cancer by PCR or next-generation sequencing
Hempelmann, J. A., Lockwood, C. M., Konnick, E. Q., Schweizer, M. T., Antonarakis, E. S., Lotan, T. L., Montgomery, B., Nelson, P. S., Klemfuss, N. M., Salipante, S. J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0341-y · Cited by 123
“Yet regardless of tumor type, conventional MSI testing is still routinely performed using PCR and fragment analysis of the 5-marker Bethesda panel (BAT-25, BAT-26, MONO-27, NR-21 and NR-24) [17, 18] and/or through immunohistochemical (IHC) detection of MMR proteins.”
BackgroundMethodInfluentialChallenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
Mulet-Margalef, N., Linares, J., Badia-Ramentol, J., Jimeno, M., Sanz, C., Mozo, J. L. M., & Calon, A. (2023) · Cancers · doi:10.3390/cancers15041022 · Cited by 124
“The Bethesda revised microsatellites markers (commonly mononucleotide BAT-25, BAT-26, NR-21, NR-4 and NR27/MONO-27) are the recommended PCR targets for the characterization of MSI/MSS status due to their stability between individuals [16,17].”
BackgroundMolecular and Computational Methods for the Detection of Microsatellite Instability in Cancer
Baudrin, L. G., Deleuze, J., & How‐Kit, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00621 · Cited by 121
“This panel has out-performed the current Bethesda panel (36, 37, 63, 67), and is currently marketed as the MSI Analysis System by Promega Corporation (Madison, Wisconsin, USA) and is also considered as a gold standard panel for MSI detection in cancer.”
MethodHechtman, J. F., Rana, S., Middha, S., Stadler, Z. K., Latham, A. J., Benayed, R., Soslow, R. A., Ladanyi, M., Yaeger, R. D., Zehir, A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0414-6 · Cited by 117
Liu, X., Jakubowski, M. A., & Hunt, J. L. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcp7fo2vaxivstp · Cited by 118
Jensen, K. C., Mariappan, M. R., Putcha, G. V., Husain, A., Chun, N., Ford, J. M., Schrijver, I., & Longacre, T. A. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31816380c4 · Cited by 113
“Identification of the MSH2/MSH6-deficient phenotype in ovarian carcinoma, particularly in women 50 years of age, may prove to be an important and cost-effective screening tool for HNPCC.”
MethodInfluentialChida, K., Kawazoe, A., Kawazu, M., Suzuki, T., Nakamura, Y., Nakatsura, T., Kuwata, T., Ueno, T., Kuboki, Y., Kotani, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0401 · Cited by 110
Mutational profiling of colorectal cancers with microsatellite instability
Lin, E. I., Tseng, L.-H., Gocke, C. D., Reil, S., Le, D. T., Azad, N. S., & Eshleman, J. R. (2015) · Oncotarget · doi:10.18632/oncotarget.5997 · Cited by 95
“Mismatch repair defects can be detected by immunohistochemical studies to determine loss of MMR proteins or functionally, by testing microsatellite length at a panel of loci [10, 11, 12].”
BackgroundEra of universal testing of microsatellite instability in colorectal cancer
Zhang, X., & Li, J. (2013) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v5.i2.12 · Cited by 103
Watson, N., Grieu, F., Morris, M. J., Harvey, J. M., Stewart, C. J. R., Schofield, L., Goldblatt, J., & Iacopetta, B. J. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060162 · Cited by 97
Microsatellite instability in the management of colorectal cancer
Pino, M. S., & Chung, D. C. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.25 · Cited by 97
High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies
Silveira, A. B., Bidard, F., Kasperek, A., Melaabi, S., Tanguy, M., Rodrigues, M. J., Bataillon, G., Cabel, L., Buecher, B., Pierga, J., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa013 · Cited by 91
“This panel has good 93 clinical sensitivity for MSI status characterization in Lynch-spectrum tumors (10, 11).”
BackgroundThe molecular biology of colorectal carcinoma and its implications: A review
Harrison, S., & Benziger, H. (2011) · The Surgeon · doi:10.1016/j.surge.2011.01.011 · Cited by 89
“Most laboratories define MSI as the presence of at least 30% unstable loci present among a panel of the five mononucleotide markers, BAT-25, BAT-26, NR-21, NR-24 and MONO-27 which are known to have a high sensitivity and specificity.(38) MSI positive tumours have also been subdivided into MSI-high and MSI-low dependin…”
A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory
van Lier, M. G., Wagner, A., van Leerdam, M. E., Biermann, K., Kuipers, E. J., Steyerberg, E. W., Dubbink, H. J., & Dinjens, W. N. M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00977.x · Cited by 89
“Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L.”
BackgroundMethodInfluentialThe clinical utility of microsatellite instability in colorectal cancer
Diao, Z., Han, Y., Chen, Y., Zhang, R., & Li, J. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103171 · Cited by 85
Pearlman, R., Markow, M., Knight, D. A., Chen, W., Arnold, C. A., Pritchard, C. C., Hampel, H., & Frankel, W. L. (2018) · Modern Pathology · doi:10.1038/s41379-018-0058-y · Cited by 83
Takamochi, K., Takahashi, F., Suehara, Y., Sato, E., Kohsaka, S., Hayashi, T., Kitano, S., Uneno, T., Kojima, S., Takeuchi, K., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.016 · Cited by 78
Waalkes, A., Smith, N. T., Penewit, K. M., Hempelmann, J. A., Konnick, E. Q., Hause, R. J., Pritchard, C. C., & Salipante, S. J. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.285981 · Cited by 77
“First, unlike MSI-PCR(14) or amplicon-based NGS MSI panels (30), smMIPs are readily and highly mutiplexable (27), such that thousands of microsatellites may be interrogated in the same assay.”
BackgroundMethodInfluentialClinical Aspects of Microsatellite Instability Testing in Colorectal Cancer
Zeinalian, M., Chaleshtori, M. H., Salehi, R., & Emami, M. H. (2018) · Advanced Biomedical Research · doi:10.4103/abr.abr_185_16 · Cited by 77
“[24,25] Rather than mononucleotide markers, pentanucleotide markers were also included in a commercial diagnostic MSI kit, Promega MSI analysis system, to identify tissue mix‐up.[24,25] It uses a multiplex fluorescent survey in which PCR of the all five mononucleotide markers and two pentanucleotide markers is done in…”
MethodChida, K., Kawazoe, A., Suzuki, T., Kawazu, M., Ueno, T., Takenouchi, K., Nakamura, Y., Kuboki, Y., Kotani, D., Kojima, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0041 · Cited by 70
“MSI and MMR status MSI status was analyzed using a Promega MSI analysis system (Promega), which used 5mononucleotide markers for the detection of MSI: BAT-25, BAT-26, NR-21, NR-24, and MONO-27 (14).”
MethodTong, G., Zhang, G., Liu, J., Zheng, Z., Chen, Y., Niu, P., & Xu, X. (2020) · Oncology Reports · doi:10.3892/or.2020.7511 · Cited by 66
Li, X., Larsson, P. G., Ljuslinder, I., Öhlund, D., Myte, R., Löfgren‐Burström, A., Zingmark, C., Ling, A., Edin, S., & Palmqvist, R. (2020) · Cancers · doi:10.3390/cancers12040923 · Cited by 67
“2 (Promega, Madison, WI, USA) consisting of mononucleotide repeats BAT-25, BAT-26, NR-21, NR-24, MONO-27 (and pentanucleotide repeats Penta C and Penta D for sample identification) [65].”
BackgroundHow Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies
Gallon, R., Gawthorpe, P., Phelps, R., Hayes, C. M., Borthwick, G. M., Santibanez‐Koref, M., Jackson, M. S., & Burn, J. (2021) · Cancers · doi:10.3390/cancers13030406 · Cited by 66
MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing
Hempelmann, J. A., Scroggins, S. M., Pritchard, C. C., & Salipante, S. J. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.05.008 · Cited by 64
Hochhauser, D., Glynne-Jones, R., Potter, V., Grávalos, C., Doyle, T. J., Pathiraja, K., Zhang, Q., Zhang, L., & Sausville, E. A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0710 · Cited by 57
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others
Bupathi, M., & Wu, C. S.-Y. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.07.03 · Cited by 61
“Following this, Promega has developed the MSI analysis system that replaced the dinucleotide markers wi th mononuc leot ide markers (NR-21, NR-24, and MONO-27) (19,20).”
MethodClinical Implications of Mismatch Repair Deficiency in Prostate Cancer
Sedhom, R., & Antonarakis, E. S. (2019) · Future Oncology · doi:10.2217/fon-2019-0068 · Cited by 60
Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?
Roon, E. H. J. V., van Puijenbroek, M., Middeldorp, A., van Eijk, R., de Meijer, E. J., Erasmus, D. D., Wouters, K. A., van Engeland, M., Oosting, J., Hes, F. J., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-180 · Cited by 59
“2, Promega, Madison, WI, US) following the recommendations of the National Cancer Institute/ICG-HNPCC [34-36].”
Patil, D. T., Shadrach, B. L., Rybicki, L. A., Heald, B., & Pai, R. K. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.98 · Cited by 58
Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma
Lewin, J. H., Davidson, S., Anderson, N. D., Lau, B. Y., Kelly, J., Tabori, U. Y., Salah, S. H., Butler, M. O., Aung, K. L., Shlien, A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0037 · Cited by 56
“S4B) from the Promega Panel of five microsatellite sites (13); however, assessing the fluorescence peaks from the MSI electrophoretograms suggested the DNA amplification was suboptimal, with the likely cause being low input DNA concentration.”
BackgroundOgino, S., Kawasaki, T., Ogawa, A., Kirkner, G. J., Loda, M. F., & Fuchs, C. S. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.005 · Cited by 56
“BAT25 and BAT26 have been shown to be among the most sensitive and specific markers for MSI-H [28].”
BackgroundIdentification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors
Gjoerup, O. V., Brown, C. A., Ross, J. S., Huang, R. S. P., Schrock, A. B., Creeden, J., Fabrizio, D. A., & Tolba, K. A. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00514-4 · Cited by 55
“Early testing of MSI was performed on only a few canonical microsatellite loci, BAT26, BAT26, D5S346, D2S123, and D17S250 (41) via PCR followed by capillary”
MethodUse of mononucleotide repeat markers for detection of microsatellite instability in mouse tumors
Bacher, J. W., Megid, W. M. A., Kent-First, M. G., & Halberg, R. B. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20146 · Cited by 55
“study in which 266 microsatellite repeat markers were analyzed in 158 tumors lacking MMR activity and 225 tumors with normal MMR activity [8].”
BackgroundSelf-citationSiemanowski, J., Schömig‐Markiefka, B., Buhl, T., Haak, A., Siebolts, U., Dietmaier, W., Arens, N., Pauly, N., Ataseven, B., Büttner, R., et al. (2021) · Cancers · doi:10.3390/cancers13061268 · Cited by 54
“PCR-based detection approaches include the Bethesda panel, already agreed on several conferences [19], as well as commercial panels [20].”
Hazama, S., Tamada, K., Yamaguchi, Y., Kawakami, Y., & Nagano, H. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12180 · Cited by 53
Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma
Dhakras, P., Uboha, N. V., Horner, V. L., Reinig, E. F., & Matkowskyj, K. A. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.01.08 · Cited by 53
“Notably, subsequent studies discovered that a panel of mononucleotide markers, which are often more unstable than dinucleotide markers, was more sensitive than the original NCI panel (41-44).”
BackgroundPatil, D. T., Bronner, M. P., Portier, B. P., Fraser, C. R., Plesec, T. P., & Liu, X. (2012) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3182461cc3 · Cited by 53
“MSI analysis was performed based on a previously described technique.(19) Briefly, the MSI test was performed using a fluorescent PCR-based assay (MSI Analysis System, Promega) by amplifying 7 loci including 5 mononucleotide repeats (BAT25, BAT26, NR-21, NR-24, and MONO-27) and 2 pentanucleotide repeats (PentaC and Pe…”
MethodImproved Detection of Microsatellite Instability in Early Colorectal Lesions
Bacher, J. W., Sievers, C. K., Albrecht, D. M., Grimes, I. C., Weiss, J. M., Matkowskyj, K. A., Agni, R. M., Vyazunova, I., Clipson, L. J., Storts, D. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132727 · Cited by 52
“A higher incidence of MSI-Low cases with the NCI panel can be attributed to the lower specificity of dinucleotide repeats for detection of MMR loss [4, 24].”
BackgroundMethodSelf-citationParente, P., Grillo, F., Vanoli, A., Macciomei, M. C., Ambrosio, M. R., Scibetta, N., Filippi, E., Cataldo, I., Baron, L., Ingravallo, G., et al. (2023) · Digestive Diseases · doi:10.1159/000531003 · Cited by 52
Patterns ofCTCFandZFHX3Mutation and Associated Outcomes in Endometrial Cancer
Walker, C. J., Miranda, M. A., O’Hern, M. J., McElroy, J. P., Coombes, K. R., Bundschuh, R. A., Cohn, D. E., Mutch, D. G., & Goodfellow, P. J. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv249 · Cited by 51
“In addition to mutations, we detected frequent LOH/allelic imbalance in the 16q22 region.”
MethodInfluentialDeschoolmeester, V., Baay, M. F. D., Wuyts, W. A., Marck, E. V., Damme, N. V., Vermeulen, P. B., Łukaszuk, K., Lardon, F., & Vermorken, J. B. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070087 · Cited by 49
“The four quasi-monomorphic mononucleotide markers were combined in a single multiplex assay as described by the step-by-step protocol of Henegariu et al.10 All CRC and 10 cervical carcinomas were used for evaluation of the multiplex PCR.”
MethodResultInfluentialBiomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
Zeng, Z., Yang, B., & Liao, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650481 · Cited by 48
Bando, H., Okamoto, W., Fukui, T., Yamanaka, T., Akagi, K., & Yoshino, T. (2018) · Cancer Science · doi:10.1111/cas.13774 · Cited by 46
Agaram, N. P., Shia, J., Tang, L. H., & Klimstra, D. S. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpgdde8plldrcc · Cited by 46
Morrison, J., Bronner, M. P., Heald, B., Downs-Kelly, E. P., Goldblum, J. R., & Liu, X. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.610003 · Cited by 45
“Microsatellite stability analyses were performed on formalin-fixed, paraffin-embedded CRC tissue and a paired normal sample according to the criteria for the determination of MSI-H as previously described [18].”
MethodPrimary Renal Cell Carcinoma in a Transplanted Kidney: Genetic Evidence of Recipient Origin
Orri, R. B., Sanz, C., Mora, M., Quer, A., Beyer, K., Musulén, E., Satué, C. G., Bayona, S., Saladié, J. M., & Ariza, A. (2009) · Transplantation · doi:10.1097/tp.0b013e31819d1e5f · Cited by 44
“In our study, we performed DNA microsatellite analysis, a currently well-established, reliable, easy to perform, and evaluate technique that is routinely used in other settings (19).”
MethodSex-Dependent Differences in Colorectal Cancer: With a Focus on Obesity
Wele, P., Wu, X., & Shi, H. (2022) · Cells · doi:10.3390/cells11223688 · Cited by 42
“are used for identification and lack the DNA mismatch repair (MMR) system [9].”
BackgroundMethodHuang, H., Lin, M., Tseng, L., Chiang, Y., Lin, L., Lin, Y., Huang, H., & Kuo, K. (2014) · Histopathology · doi:10.1111/his.12543 · Cited by 40
“The neoplasm was designated as MSI-H if novel allele lengths were identified in the neoplastic cells as compared with normal/germline cells at two or more microsatellite loci.(15)”
BackgroundMethodSøreide, K. (2007) · Tumor Biology · doi:10.1159/000110427 · Cited by 39
Pastrello, C., Baglioni, S., Tibiletti, M. G., Papi, L., Fornasarig, M., Morabito, A., Agostini, M., Genuardi, M., & Viel, A. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201517 · Cited by 39
Frydendahl, A., Kassentoft, C. G., Knudsen, M., Laursen, M. B., Madsen, A. H., Iversen, L. H., Gotschalck, K. A., Rasmussen, M. H., & Andersen, C. L. (2019) · BMC Cancer · doi:10.1186/s12885-019-6227-7 · Cited by 38
“Although widely used, discrepancy is commonly reported between the methods [42 – 44].”
MethodLeGolvan, M. P., Taliano, R., & Resnick, M. B. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.03.003 · Cited by 38
“A similar panel is available commercially (MSI Analysis System; Promega, Madison, WI) [26] and, when compared with the Bethesda panel, had excellent correlation between MSI-H and MSS cases, with the only discrepancy being that all Bethesda panel MSI-L cases were classified as MSS by MSI Analysis [27].”
Microsatellite instability analysis of sinonasal carcinomas
Martínez, J. G., Pérez‐Escuredo, J., López, F., Suárez, C., Álvarez‐Marcos, C., Llorente, J. L., & Hermsen, M. A. J. A. (2009) · Otolaryngology · doi:10.1016/j.otohns.2008.10.038 · Cited by 38
“Examples are TGF- RII and BAX in colorectal cancer.(16) In a way this mechanism is Table 1 Clinical features and MSI results of 41 ITACs”
BackgroundCAT25 Is a Mononucleotide Marker to Identify HNPCC Patients
Bianchi, F., Galizia, G., Catalani, R., Belvederesi, L., Ferretti, C., Corradini, F., & Cellerino, R. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080155 · Cited by 37
Gallon, R., Sheth, H. J., Hayes, C. M., Redford, L., Alhilal, G., O'Brien, O., Spiewak, H. L., Waltham, A., McAnulty, C., Izuogu, O. G., et al. (2019) · Human Mutation · doi:10.1002/humu.23906 · Cited by 36
“These methods are highly sensitive and specific, with reported sensitivities and specificities of 93% and 95% for IHC of all four MMR proteins (Shia, 2008), and 97% and 100% for FLA of mononucleotide repeats (MNRs; Bacher et al., 2004).”
BackgroundZhou, Z., Xie, X., Wang, X., Zhang, X., Li, W., Sun, T., Cai, Y., Wu, J., Dang, C., & Zhang, H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.623424 · Cited by 35
Nardon, E., Glavač, D., Benhattar, J., Groenen, P. J. T. A., Höfler, G., Höfler, H., Jung, A., Keller, G., Kirchner, T., Lessi, F., et al. (2010) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3181db67af · Cited by 35
Application of molecular diagnostics for the detection of Lynch syndrome
Pino, M. S., & Chung, D. C. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.45 · Cited by 34
Colorectal Cancer Screening: A Comprehensive Review to Recent Non-Invasive Methods.
Hamzehzadeh, L., Yousefi, M., & Ghaffari, S. H. (2017) · PubMed Central · Cited by 34
Tapial, S., López, S. O., Rueda, D., Arriba, M., García, J. L., López, A. V., Pérez, J., Pena-Couso, L., Olivera-Salazar, R., Rodríguez, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47014-w · Cited by 34
Immunohistology of the Female Genital Tract
Rabban, J. T., Soslow, R. A., & Zaloudek, C. Z. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5766-6.00022-4 · Cited by 34
Ilm, K., Kemmner, W., Osterland, M., Burock, S., Koch, G., Herrmann, P., Schlag, P. M., & Stein, U. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0316-2 · Cited by 33
“MSI Analysis System was used for MSI status determination as described previously [16].”
Huang, Y., Yuan, Y., Ge, W., Hu, H., Zhang, S., & Zheng, S. S. (2010) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1000198 · Cited by 33
“Bacher et al. (2004) evaluated a set of 266 mono-, di-, tetra-, and penta-nucleotide repeats loci for potential use in MSI screening.”
BackgroundRole of c-Abl Kinase in DNA Mismatch Repair-dependent G2 Cell Cycle Checkpoint Arrest Responses
Wagner, M. W., Li, L. S., Morales, J. C., Galindo, C. L., Garner, H. R., Bornmann, W. G., & Boothman, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709953200 · Cited by 31
What's New in Hereditary Colorectal Cancer?
Jass, J. R. (2005) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2005-129-1380-wnihcc · Cited by 32
Tang, Y., Chen, T., Zhang, Y., Zhao, X., Zhang, Y., Wang, G., Huang, M., Cai, S., Zhao, J., Wei, B., et al. (2019) · Gastroenterology report · doi:10.1093/gastro/goaa045 · Cited by 30
Yu, F., Makrigiorgos, A., Leong, K. W., & Makrigiorgos, G. M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.037 · Cited by 30
“However, due to the low resolution in fragment size and timeconsuming pitfall, it was substituted by a new procedure, in which makers are amplified with fluorescent primers and subsequently examined by capillary electrophoresis for microsatellite allele size [25,33].”
BackgroundMethodMicrosatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions
Moon, C., Gordon, M., Moon, D., & Reynolds, T. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312864 · Cited by 21
Agostini, M., Enzo, M. V., Morandi, L., Bedin, C., Pizzini, S., Mason, S., Bertorelle, R., Urso, E. D. L., Mescoli, C., Lise, M., et al. (2009) · Cancer Biomarkers · doi:10.3233/cbm-2009-0118 · Cited by 30
Metadata
- Authors
- Bacher, J. W., Flanagan, L. A., Smalley, R. L., Nassif, N. A., Burgart, L. J., Halberg, R. B., Megid, W. M. A., & Thibodeau, S. N.
- Affiliations
- Promega (United States) (US)
- Mayo Clinic (US)
- Corresponding author
- Bacher, Jeffery W.
- Venue
- Disease Markers
- Publisher
- Wiley
- Published
- 2004-01
- Volume
- 20
- Issue
- 4-5
- Pages
- 237-250
- ISSN
- 0278-0240 (ISSN-L)
- 1875-8630
- PMC
- PMC3839403
- OpenAlex
- W2104818405
- Cited by
- 276
- References
- 49
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 15 · 2023: 20 · 2022: 16 · 2021: 33 · 2020: 21 · 2019: 11 · 2018: 19 · 2017: 13 · 2016: 10 · 2015: 11 · 2014: 9 · 2013: 9 · 2012: 10
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Disease Markers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (CA-76834)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- microsatellite instability, mismatch repair deficiency, Lynch syndrome, BAT25, BAT26, colorectal neoplasia, gastrointestinal cancer
- MeSH terms
- Alleles, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Mutational Analysis, Fluorescent Dyes, Gastrointestinal Neoplasms, Gene Frequency, Humans, Immunohistochemistry, Microscopy, Fluorescence, Mutation, Oligonucleotides, Phenotype, Prognosis, Sensitivity and Specificity, Biomarkers, Tumor, Colorectal Neoplasms, Polymerase Chain Reaction, Microsatellite Repeats, DNA Sequence, Unstable
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.